-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $280

Benzinga·08/04/2026 12:35:15
語音播報
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $245 to $280.